UPMC Enterprises has contributed to a $117m series B round for gene therapy developer Ring Therapeutics.
Ring Therapeutics, a US-based gene therapy developer, has secured $117m in a series B round backed by UPMC Enterprises, the commercialisation arm of University of Pittsburgh Medical Center, a health system closely aligned with the institution.
The round was also backed by Flagship Pioneering, Invus, Altitude Life Science Ventures, Partners Investment, funds and accounts advised by T Rowe Price Associates and unnamed others.
Founded in 2017 by Flagship Pioneering, Ring Therapeutics is working on anellovirus-based vector candidates for gene therapies.
…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
